Daniel Estandian

Daniel Estandian is the Co-Founder and Chief Technology Officer (CTO) of Glyphic Biotechnologies, a biotechnology startup focused on revolutionizing protein sequencing.13

Background and Education

Estandian has a strong academic background in molecular biology and biotechnology:

• He holds a bachelor's degree in molecular biology from UC Berkeley.2
• He pursued his Ph.D. at MIT, where he developed a molecule called ClickP, which became foundational to Glyphic's technology.2

Career and Entrepreneurship

Estandian's career in biotechnology spans over a decade:

• He began his research career in 2011 as an Undergraduate Researcher in the Yang Dan Lab.6
• After completing his Ph.D., Estandian co-founded Glyphic Biotechnologies in 2021 with Joshua Yang.13

At Glyphic Biotechnologies, Estandian and his team are developing a first-of-its-kind, next-generation protein sequencing platform. Their goal is to enable researchers to gain novel insights into biology and disease.3

Expertise and Recognition

Estandian is recognized for his expertise in protein sequencing:

• He is described as a "brilliant thinker and revolutionary in the protein sequencing space".4
• His work is expected to make a significant impact across the biotech industry.4

Company Leadership

As the CTO of Glyphic Biotechnologies, Estandian plays a crucial role in the company's technological development:

• He leads a multidisciplinary team working on building a Next-Generation Protein Sequencer.5
• Under his leadership, Glyphic has grown to 28 employees and secured $44 million in total investment.3

Daniel Estandian's LinkedIn profile can be found at linkedin.com/in/daniel-estandian-31492651.4